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Abstract
Background Despite the benefits biosimilars offer in terms of cost savings and patient access, healthcare professionals and 
patients have been reluctant to use them. Next to insufficient understanding of and trust in biosimilars, healthcare profes-
sionals and patients have questions about switching and the nocebo effect when using biosimilars in clinical practice. In 
addition, clear motivation to use biosimilars may be lacking among these stakeholders.
Objective This study aims to provide recommendations on how to improve biosimilar use on both a clinical and a practical 
level based on insights from healthcare professionals (physicians, hospital pharmacists, nurses), patients (or their representa-
tives), and regulators across Europe.
Methods We conducted 44 semi-structured interviews with experts from five stakeholder groups across Europe: physicians, 
hospital pharmacists, nurses, regulators, and patients/representatives. Interviews were transcribed ad verbatim and transcripts 
analysed according to the thematic framework method.
Results Based on the insights and considerations of the experts interviewed, we identified a number of recommendations to improve 
the use of biosimilars in clinical practice. Regarding switch implementation, the experts voiced support for the following actions: (1) 
disseminate evidence from and experience with (multiple) switching; (2) provide clear, one-voice regulatory guidance about the inter-
changeability of biosimilars and their reference product; (3) apply a multi-stakeholder implementation and communication protocol to 
guide switching in clinical practice; (4) apply a pragmatic approach when taking switch decisions; and (5) avoid mandated switching, 
allowing stakeholder communication and alignment. When discussing approaches to increase the willingness of stakeholders to use 
biosimilars, we concluded that actions should be centred on (1) communicating the benefits provided by biosimilars and the introduc-
tion of market competition, (2) increasing awareness among stakeholders about medicine prices and their societal responsibility to use 
medicines in a cost-effective manner, (3) transparent reporting about the allocation of savings, (4) sharing biosimilar usage data among 
hospitals and prescribers to allow peer-to-peer benchmarking, and (5) applying a balanced combination of tangible and non-tangible 
incentives that can be tailored to offset the time and effort expended by stakeholders when switching to a biosimilar.
Conclusions This study proposes a number of strategic, practical, and overarching recommendations to support healthcare 
professionals and inform decision makers to improve the clinical use of biosimilars and the willingness of stakeholders to 
use them. The proposed solutions to fully realise the potential of biosimilars for healthcare systems and patients include 
developing practical switch guidance, being transparent about the gains from biosimilar use (and how savings are allocated), 
and developing a combination of non-tangible and tangible incentives for involved stakeholders.
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1 Introduction
With the patent protection and other exclusivity rights of an 
increasing number of original biological medicines (also called 
reference products) expiring, interest in the development and 
commercialization of biosimilars has soared [1]. Biosimilars can 
reduce treatment costs by introducing market competition and 
thus relieve increasing budgetary pressure on healthcare sys-
tems. In addition to having an impact on pharmaceutical spend-
ing, biosimilar market entry has also been shown to increase 
patient access to these formerly expensive biologicals [1, 2].
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Key Points 
Despite the benefits offered by biosimilars, they are not 
being widely adopted and prescribed. Healthcare profes-
sionals and patients have questions regarding the use 
of biosimilars, particularly regarding switching and the 
nocebo effect. In addition, prescribers may lack a clear 
motivation to use biosimilars.
This study proposes several strategic, practical, and over-
arching recommendations to support healthcare profession-
als and inform decision makers to improve the clinical use 
of biosimilars and encourage stakeholders to use them.
Developing practical switch guidance, transparently 
communicating the gains from biosimilar use (and how 
savings are allocated), and developing a combination 
of tangible and non-tangible incentives for involved 
stakeholders will contribute to realizing the full potential 
of biosimilars.
the vast majority of studies did not indicate any major safety, 
efficacy, or immunogenicity issues associated with this [10, 
11]. However, a number of real-world studies have reported 
a relatively high therapy discontinuation rate among patients 
after switching, which was mostly attributed to the occur-
rence of the nocebo effect [10]. The nocebo effect is defined 
as a negative impact on the patient’s perceived treatment 
outcome resulting from the patient’s negative expectation 
about the (change in) therapy [12, 13]. To support HCPs 
and patients in their use of biosimilars, guidance on switch 
implementation and mitigation of the nocebo effect is 
required.
In addition, biosimilar use may be hampered by a lack of 
motivation among HCPs and patients, as stakeholders are 
unlikely to change behaviour without an incentive [6, 7]. 
Although several European countries are testing gainsharing 
models, where savings generated from biosimilar compe-
tition are shared among stakeholders [5], experience with 
these arrangements remains fairly new [14]. Insights into the 
willingness of stakeholders to use biosimilars and the design 
of appropriate incentives may help decision makers improve 
biosimilar policy making.
This article is the second part of a study on European 
multi-stakeholder lessons regarding biosimilars. It aims to 
provide recommendations—based on insights from physi-
cians, hospital pharmacists, nurses, patients (or their rep-
resentatives), and regulators across Europe—on how to 
improve biosimilar use, both clinically (e.g. how to imple-
ment a switch) and practically (e.g. how to organize stake-
holder incentives).
2  Methods
This study consisted of 44 semi-structured interviews 
[described elsewhere [8] and included in the electronic supple-
mentary material (ESM) 1] with biosimilar experts across five 
stakeholder groups (physicians, hospital pharmacists, nurses, 
patients, and regulators) to gain insights about how to improve 
the clinical and practical use of biosimilars in Europe.
3  Results
In total, 44 interviews were carried out. Participant charac-
teristics are shown in ESM 1.
3.1  Towards Improved Biosimilar Use in Clinical 
Practice
Stakeholder challenges and proposals to improve biosimilar 
switch implementation are shown in Fig. 1.
Since the first biosimilar approval in Europe in 2006, 
more than 55 biosimilars have received marketing authori-
zation in Europe [3]. So far, rates of biosimilar use have 
varied across member states and product classes and in 
some cases have been limited [1, 4]. The differences in 
uptake across European countries and regions may partly 
be explained by varying biosimilar (market entry) policies 
[1, 5]. Furthermore, despite the potential of biosimilars to 
positively impact expenditure and patient access, biosimi-
lar adoption may be hampered by reluctance on the part 
of both healthcare professionals (HCPs) and patients to use 
biosimilars because of a lack of trust in and understanding 
of them [6, 7]. In the first article of this series on biosimilar 
multi-stakeholder insights, we provided recommendations 
on how to improve HCP and patient biosimilar understand-
ing in Europe [8].
In clinical practice, HCPs are faced with questions 
regarding the use of biosimilars. As biological medicines 
are often used in chronic treatment settings, use of a bio-
similar may involve switching a patient from a reference 
product to a biosimilar. Since their introduction in Europe, 
and especially with the introduction of monoclonal antibody 
biosimilars, the safety of switching a patient between highly 
similar but non-identical products has been questioned [9], 
and this has left HCPs uncertain about using biosimilars 
[6]. Several randomized, controlled and real-world studies 
have evaluated the efficacy, safety, and immunogenicity of 
switching from reference products to biosimilars. Overall, 
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3.1.1  What to Consider When Deciding to Switch
Most physicians, pharmacists, and nurses found that patients 
may be switched safely and felt reassured by the available 
data regarding switching. Although some patients also felt 
reassured by the available data, several remained hesitant 
about switching. Some patients requested studies over a 
longer timeframe to better evaluate the long-term effects 
of switching. Furthermore, the willingness to switch could 
depend on the product’s complexity. Several interviewees 
argued that the uncertainty surrounding switching mostly 
resulted from misinformation from the pharmaceutical 
industry.
Several HCPs advocated for a pragmatic approach when 
deciding whether to switch. Initiating only bio-naïve patients 
with a biosimilar in certain cases, such as shorter treatment 
periods, was preferred: “It would be a lot of hassle and time 
investment to switch a patient in the last four months of 
[their] treatment.” Also, several patients favoured only start-
ing new patients with a biosimilar, regardless of the treat-
ment setting (acute vs. chronic).
Forcing a switch was believed to be counterproductive 
and could result in distrust of biosimilars. Across stakehold-
ers, most interviewees felt that the physician should remain 
in control of treatment decisions and be able to decide 
whether to switch based on individual patient circumstances. 
It was believed that giving patients the option to return to the 
reference product would reassure patients.
Several interviewees argued for continued monitoring and 
ensuring product traceability when switching.
3.1.2  How to Implement a Switch and Minimize 
the Nocebo Effect
Almost all interviewees indicated that switching should fol-
low a structured process that is agreed upon and carried 
out by an aligned HCP team. Several pharmacists explained 
that the switch should follow a stepwise approach. First, a 
discussion about the switch should be organized among the 
relevant stakeholders, allowing for shared decision making. 
Second, the patient should be informed that a switch will 
be organized at the next administration. Some interviewees 
referred to the Dutch Association of Hospital Pharmacists 
(NVZA) toolbox [15] as a supporting tool to implement a 
structured switch. Careful planning was considered neces-
sary: “building trust takes a lot of time, and only one inci-
dent to dissolve [it] again.”
• Create stakeholder confidence about biosimilars to reduce the 
stakeholder need for additional data generation 
Stakeholder challenges Stakeholder aligned recommendations
• Design and implement a stakeholder incentive to lower threshold 
• Involve a specialized nurse to support the switch process 
• Develop and provide guidance about switching (protocol)
• How to organize a structured switch approach 
• How to effectively communicate to the patient, circumventing a 
possible nocebo effect
• Develop one-voice regulatory interchangeability and switching
guidance
• Increase collaboration between authorities and HCPs
• Translate regulatory guidance into practical stakeholder info
• Educate about and disseminate clinical switch data
• Share positive switch experiences 
• Uncertainty about the safety of switching, partly due to 
misinformation and industry influence leading to a lack of 
stakeholder confidence
• Guidance lacking or unclear about
• Switch implementation strategies 
• Nocebo effect management 
• Switching and interchangeability (no overarching  
EU position, incomplete patchwork of position 
statements on national level)
• Possible additional investment and time-to-market hurdle 
for developers to conduct additional switch studies beyond 
licensing requirements as response to stakeholder 
uncertainty 
• HCP time and effort threshold to switch a patient 
• A lack of motivation (“what’s in it for me?”)
• Involve physicians in the switch decision and avoid mandated/top-down 
organized switching 
• Avoid frequent switches
• Provide the opportunity for motivated exceptions 
• In some cases, it may be more pragmatic to only start bio-naïve patients 
with the biosimilar (e.g. short treatment duration) 
• Fear of losing control of treatment and traceability with 
(multiple) switching
How to overcome stakeholder hurdles related to switching in clinical practice
Fig. 1  How to overcome stakeholder hurdles related to switching in clinical practice—proposed multi-stakeholder actions. HCPs healthcare pro-
fessionals
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Several interviewees contended that the HCP team must 
be well informed and educated to coherently communicate 
and transfer confidence to the patient. Informing patients 
with an aligned, unified message was deemed essential. Ver-
bal and non-verbal signals from HCPs could also impact the 
patient’s perception: “If the nurse looks unsure and cannot 
respond satisfactorily to questions, it doesn’t build patient’s 
trust.” Several interviewees believed that the physician’s 
confidence is key to minimizing a nocebo effect, as “the 
patient is confident when the physician is confident.” Moreo-
ver, a specialized nurse may help to guide the switch process 
more smoothly.
Several interviewees voiced that patient concerns and 
possible nocebo effects need to be taken seriously: “To 
patients, those effects feel very real” and “Switching them 
from an active drug that induced remission of a previ-
ously very impactful disease is very sensitive.” One patient 
remarked that distinguishing between a nocebo-related and 
true side effect may prove challenging. Several interviewees 
mentioned that communication should be fully transparent 
to build trust between patient and provider.
Almost all interviewees mentioned that starting a dia-
logue with the patient and informing them about the switch 
is important. Several nurses, physicians, and regulators con-
sidered that dedicating time to explain the change to the 
patient was a necessity. Although interviewees generally 
agreed that patients should be informed about the switch, 
they disagreed about exactly how to involve them, with most 
believing that patients should not be involved in the decision 
making and others arguing that patients should be involved 
to reduce reluctance, avoid nocebo effects, and build trust 
in their HCPs.
There was no consensus over the level of detail that 
patients should receive about biosimilar concepts. One 
nurse argued, “If the HCP tells the patient that the medi-
cine is good, it is not very interesting for the patient if it 
is an original drug or a biosimilar.” Several nurses voiced 
that patient communication should not be overcomplicated: 
“Now we said ‘Well, we don’t have the original product, so 
we treat everybody with the biosimilar’, and I haven’t heard 
any problems.” One nurse questioned the need to inform 
patients about biosimilars altogether: “It is an ethical prob-
lem. Must you inform patients when in fact there is no dif-
ference for them as far as you expect?” Another interviewee 
mentioned that no questions were asked when they switched 
to a filgrastim biosimilar: “Everybody called it another type 
of growth factor. As it was communicated that the product 
had all the same side effects and the same precautions were 
needed, there was no big deal about it.” Several interviewees 
considered that striking a balance between the amount and 
type of information to provide to patients is challenging: “A 
patient might be triggered to think that there is something 
wrong if a lot of emphasis is put on the switch.”
Most interviewees mentioned that patients need to be 
informed as to why a switch is being made and about its 
positive impact. Some interviewees counter-argued that not 
all patients are interested in the cost benefit. Furthermore, 
it was argued that it should be made clear to the patient that 
less expensive does not equal inferior when discussing the 
financial benefits of the switch.
Generally, it was believed that information should be 
centred on explaining that the biosimilar is equally as safe 
and effective as the reference product and that patients may 
expect the same outcomes. Both nurses and patients consid-
ered that reassurance regarding safety was important. Some 
regulators claimed that the nocebo effect may be minimized 
if HCPs and patients were informed that biosimilars are only 
authorized if their efficacy and safety profiles are shown to 
be equal to those of the reference product.
Several interviewees across the groups advised that infor-
mation should include the practical implications for the 
patient: “what does the switch mean for the patient.” It was 
mentioned that patients should be provided with a contact in 
case they have questions or experience adverse effects. Other 
patient-communication aspects that were deemed important 
were to inform patients in a timely manner, provide multiple 
opportunities to discuss the switch, and provide follow-up 
after the switch. Some patients mentioned that additional 
follow-ups could serve as opportunities to monitor for side 
effects.
It was stated that patient information should be under-
standable, readable, and concise. Layman’s terms (such as 
those used in the patient biosimilar question & answer bro-
chure from the European Commission [EC] [16] or the Dutch 
Medicines Evaluation Board biosimilar booklet [17], repeat-
edly mentioned as examples) should be used, and materials 
should be available in the patient’s first language. Providing 
written information that patients can read and re-read was 
considered important. Several interviewees argued that there 
is no one-size-fits-all approach for good patient communica-
tion and that tailoring the communication strategy and level 
of detail to the needs and wishes of the patient is important.
Several interviewees mentioned that special considera-
tion should be given to patients who self-administer their 
therapy, as they may need to receive training about the injec-
tion device.
One physician argued that patient communication should 
focus on the medicine’s international nonproprietary name, 
as this requires a less active mindset shift among patients 
when switching as physicians are able to maintain their treat-
ment terminology.
Several HCPs and one patient mentioned that the patient’s 
treatment outcome expectations should be managed, as 
response to treatment may naturally wane over time for cer-
tain types of medicines. Patient trust in the HCP may be 
negatively affected if this were to coincide with the timing 
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of the switch: “It would only take one patient treated with 
infliximab that reached tolerance at the same time as the 
switch to undermine our complete programme.”
Furthermore, interviewees mentioned that objectively 
assessing any changes before and after the switch by 
monitoring specific disease parameters for certain product 
types and patients may help to reassure patients and HCPs 
throughout the switch process.
In summary, the general opinion was that a switching 
operation should be set up as a multi-stakeholder project, 
with clear decision lines, education for a unified approach, 
and a well-planned implementation and follow-up procedure.
Figure 2 provides a structured overview of key steps 
regarding switch management.
3.1.3  Multiple Switching, Switching Between Biosimilars 
of the Same Reference Product, and Switching 
Between Administration Routes
Several HCPs and patients had reservations about multi-
ple switching and indicated that constant changes should 
be avoided. It was argued that more information and data 
were needed because of a lack of experience with this. Some 
interviewees mentioned that data on multiple switches are 
increasingly being generated. Several physicians contended 
that multiple switching discussions are misused to “bring 
noise to the discussion,” as it suggests that the physician 
could lose control over the process. Overall, most physi-
cians and nurses maintained that frequent switches should 
be avoided because it could lead to traceability issues and 
confusion among the HCPs and patients involved. It was 
mentioned that agreements about multiple switching should 
be made with the payer or hospital: “Now we decide that we 
can switch everyone, but that we cannot switch again within 
the first years. This is not based on evidence, it’s based on 
distrust, thinking that there are long-term effects. Over the 
next years, a discussion about multiple switching is needed.” 
Questions arose about what would be considered an accept-
able interval between switches. Furthermore, several inter-
viewees argued that a pragmatic approach should be taken 
to avoid multiple switching of patients receiving chronic 
treatment: “Patients cannot be switched all the time.” Also, 
some reasoned that the cost savings of a second switch could 
be limited.
Most physicians and pharmacists considered switching 
between biosimilars of the same reference product accept-
able: “For me it is the same as switching between reference 
product and biosimilar. You have again a high level of simi-
larity.” It was not deemed necessary to provide confirmatory 
Set up a structured switch plan Inform the patient Organize the switch moment Provide follow-up moment 
• Manage the switch as a project
with assigned responsibilities
and regular feedback on
progress
• Apply a multi-stakeholder
shared decision-making:




• Ensure that the HCPs team is
well informed and trained
• Communicate with one voice, to
ensure a good information and
trust transfer to the patient
What to communicate
• Explain the reasons behind the
switch, illustrating the positive
impact
• Explain that the product is
equally safe and effective
• Explain any practical
implications (e.g. difference in
injection device)
• Explain what to do in case of
complaints
• Apply standard of care
• If applicable, train patient on
new injection device
• Plan the switch moments over
time (not all patients at the same
time)
• Routinely follow up the patient
• Provide the opportunity for a
follow-up communication
moment (telephone/in person) to
the patient
• Provide opportunity to report
back any adverse events,…
How to communicate
• Communicate with a focus on
INN




• Provide written information in
the patient’s mother tongue
• Take time to explain
Allow tailoring based on the informational needs of the patient, no one-size-fits-all approach
Key elements on how to organize a switch in clinical practice and avoid the nocebo effect
Fig. 2  Key elements on how to organize a switch in clinical practice and avoid the nocebo effect—multi-stakeholder insights. HCPs healthcare 
professionals, INN international nonproprietary name
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data in this regard. Sharing experiences and registries of bio-
similar-to-biosimilar switches was considered informative 
for stakeholders. Some regulators doubted that developers 
would be interested in investing in biosimilar-to-biosimilar 
switch studies. Most nurses were hesitant about biosimilar-
to-biosimilar switching because of a lack of practical experi-
ence with this.
It was argued that switching between different administra-
tion routes (i.e. from subcutaneous to intravenous products 
or vice versa) occurred often in clinical practice and that 
physicians considered it clinically unproblematic. How-
ever, changes at organizational and logistical levels would 
be required. In addition to these practical considerations, it 
was suggested that the patient’s preference should be consid-
ered, as the change could have an impact on the patient’s life 
(e.g. home vs. hospital administration, or the level of contact 
with HCPs). Most interviewees would prefer to maintain 
patients receiving subcutaneous treatments on their current 
treatment but start treatment-naïve patients with the lower-
priced intravenous formulation. In contrast, one pharmacist 
argued that it would be fair to ask patients to switch back to 
intravenous administration if it would allow more patients 
to be treated. Participants also argued that, depending on the 
hospital’s organisation, any discounts provided by biosimilar 
competition for intravenous products would need to offset 
the possible increase in day clinic costs.
3.1.4  Stakeholder Opinions Regarding Substitution 
for Biologicals
Overall, most physicians and pharmacists were not against 
pharmacist substitution per se, provided that the physician 
is informed about the change, stressing the importance of 
physicians remaining in control over the treatment. Several 
patients also emphasized that the patient should be informed 
about any change. Physicians strongly opposed automatic 
substitution (i.e. change by the pharmacist without inform-
ing the physician), as this would lead to a loss of control 
and possibly to multiple subsequent transitions. Most nurses 
did not object to substitution as they deemed it a physician/
pharmacist decision and responsibility: “If we agree that 
biosimilars are as safe and effective as the originator, and we 
can treat more people and reduce the cost for the healthcare 
system, why shouldn’t we do automatic substitution?”
Overall, several interviewees considered that substitu-
tion practices for biologicals would likely evolve over time 
and perhaps be introduced in the future. Most interviewees 
emphasized that introducing substitution for [monoclonal 
antibody (mAb)] biologicals would be premature, as the 
level of trust in biosimilars is still considered too fragile: 
“Everyone is still learning about biosimilars.” Enforcing or 
prematurely introducing substitution could negatively affect 
the acceptance of biosimilars. Most pharmacists compared 
the discussions about substituting biologicals with those 
at the time of generic market entry. Similarly, the debate 
was considered to stem from fears that the patient would 
not respond as well to the treatment and that there would 
be problems tracking which product the patient receives. 
Another pharmacist argued that, as the originator also 
changes over time because of manufacturing changes, the 
patient is already exposed to different versions over time.
In addition to psychological considerations, several reg-
ulators and pharmacists explained that organizational and 
policy barriers exist: “Substitution could be done, but the 
conditions need to be appropriate.” An information system 
that allows good pharmacist–physician communication is 
necessary. Furthermore, some pharmacists mentioned that a 
clear mandate from national authorities is required. Several 
interviewees also stated that an adequate system for report-
ing adverse reactions is essential. Pharmacists should also 
be trained to educate patients about a possible (change in) 
injection device. Alternatively, specialized pharmacies could 
be nominated to carry out substitution.
Furthermore, interviewees also noted that differentia-
tion between therapeutic areas and product types could be 
applied (proportionality of risk) and physicians should be 
allowed to veto a substitution if appropriately motivated. For 
example, where product effects are known to possibly wane 
over time, development of tolerance at the time of substi-
tution could adversely affect the patient–HCP relationship.
Stakeholder considerations regarding substitution for bio-
logicals are shown in Fig. 3.
3.2  Towards Improved Stakeholder Willingness 
to Use Biosimilars: Biosimilar Value Proposition 
and Stakeholder Incentives
Stakeholder-specific considerations are presented in Figs. 4 
and 5.
3.2.1  Reasons to Use Biosimilars and Possible 
Differentiators Between Products
Generally, the lower price of biosimilars was recognized as 
the most important benefit, with some viewing it as the only 
benefit. Several interviewees acknowledged that, with the 
introduction of market competition, savings could also be 
derived from reduced prices for reference products. Some 
interviewees argued that biosimilars should not be favoured 
per se over the reference product, as the price of the refer-
ence product will generally also decrease.
Interviewees often mentioned that lower treatment 
prices could translate to improved patient outcomes as 
more patients could be treated within the same budget or 
patients could be treated earlier in the treatment pathway as 
it becomes more cost effective to do so.
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Some interviewees reasoned that biosimilar savings could 
create budgetary headroom for the reimbursement of inno-
vative medicines. Some mentioned increased freedom for 
physicians to prescribe new therapies as a benefit.
Some interviewees argued that reasons to use biosimilars 
will vary regionally. In regions with good access to bio-
logical therapies, savings derived from biosimilar use are 
expected to be reinvested in the reimbursement of innovative 
medicines, whereas in regions with limited access, biosimi-
lar entry could translate to increased patient access.
Several physicians and regulators indicated that bio-
similars could also improve delivery of care, including 
improvements in the administration device or by providing 
administration routes that do not (yet) exist with the ref-
erence product. Furthermore, packaging differences can 
potentially impact positively on patient co-payments (e.g. 
introducing more units per package while retaining the same 
out-of-pocket cost). Respondents thought these differentia-
tion strategies could stimulate originator companies to also 
introduce extra services, and one patient mentioned that the 
availability of different products could positively impact the 
patient’s product choice.
Some pharmacists mentioned that the availability of 
biosimilars (i.e. the presence of different suppliers of the 
product) could also be beneficial to secure supply in case 
of shortages.
• Emotional barriers 
• More trust and experience with biosimilars may need to be 
gained by stakeholders before introduction of substitution 
• Physicians fear to lose control over treatment 
• Current landscape considered too fragile
• Practical barriers
• Pharmacists and systems (e.g. physician-pharmacist 
communication systems outside of the hospitals) may be 
insufficiently prepared 
• In most European countries, no mandate given to pharmacists to 
substitute biologicals 
• Could be considered in future years when practical and emotional 
barriers are addressed 
• Elements on how to organize:  
• Always inform the physician: no automatic substitution
• Allow motivated exceptions for specific products or patients
• Clear mandate from the National Competent Authority 
• Practical communication system between physician and 
pharmacist 
• Reliable system for reporting of adverse events 
• Patient counseling by pharmacist in case of change in injection 
device
Stakeholder considerations about current context Outlook on possible future substitution
Stakeholder considerations about (automatic) substitution
Fig. 3  Stakeholder considerations about (automatic) substitution
Lowered treatment costs
• Lower priced biosimilar
• Price competition upon 
biosimilar market entry
• Lower priced 
reference product 
• Lowered prices in 
broader therapeutic 
class* 
Increased patient access to 
biological treatment
• More patients treated within 
the same budget
• Earlier treatment of patients 
with a biological due to 
improved cost-effectiveness 
(advancing therapy to an 
earlier treatment-line)
Improved delivery of care
• Support from specialized 
nurse
• Differentiation and 
improvements in injection 
device
• Value-added services (e.g. 
disease programs to enhance 
patient adherence)**
Lowered patient co-payment
Reinvestment of savings in 
reimbursement of innovative 
medicines
Depending on the region/country, the value offered by biosimilars (balance between benefits) may be different 
Innovation in biologicals 
development (product 
differentiation)
• New administration routes
• New indications
• New formulations*** 
• Next-generation 
biologics***
Towards savings Towards the patient/care Towards innovation
What are advantages offered by biosimilars according to stakeholders? 
Plurality in suppliers, 
beneficial in case of shortages
Fig. 4  What are the advantages offered by biosimilars according to stakeholders? Asterisks indicate possible benefits from biosimilars men-
tioned in the literature that were not mentioned during the expert interviews. *QuintilesIMS [32]; **Simoens and Cheung [33]; ***Dutta et al. 
[34]
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Several interviewees remarked that more effort is required 
to ensure that the market becomes or remains sufficiently 
attractive, ensuring continued investment in the development 
of new and market presence of already approved biosimilars. 
A few interviewees mentioned that decreased interest in the 
biosimilar segment and subsequent competition may lead to 
shortages. “If prices are driven down too much, some play-
ers will go out of the market, certainly in smaller markets, 
putting such markets at risk of drug shortages.”
Most interviewees identified price as the main, or 
sole, differentiator between the reference product and its 
biosimilar(s), as they perform equally in terms of efficacy 
and safety. Some interviewees considered factors beyond 
price when choosing between products. These included 
supply reliability, value-added services such as information 
support, and the delivery device and injection material for 
subcutaneous products. Some nurses argued that the patient 
friendliness of the product and its ease of use should be 
assessed together with the patient. The presentation of dif-
ferent concentrations was mentioned by a few pharmacists 
as another possible differentiator.
It was argued that additional services should be con-
sidered as a bonus and should not trump price differences. 
Some interviewees questioned the value of some differen-
tiators, such as the citrate-free formulation for some adali-
mumab products: “How much weight do we want to award 
to these, sometimes, low impact differences?” Several phar-
macists advocated for transparent award criteria to assess 
differentiators.
3.2.2  Motivating Stakeholders to Use Biosimilars
3.2.2.1 Creating Awareness About Medicine Prices and Call-
ing Upon Stakeholders’ Societal Responsibility Some inter-
viewees expressed the need for increased awareness of med-
icine prices among HCPs and the public. Several regulators 
and physicians argued that it is the duty of the physician 
to prescribe and that of the society to use medicines in a 
cost-effective manner: “As a society, we have the obliga-
tion to look at the economic aspects once the product is 
considered equal.” Some physicians and regulators argued 
that decisions should be made from a common good per-
spective (“what is best for society”) and that the stakehold-
ers involved should not expect compensation. As a Danish 
nurse mentioned, “It is money for the Danish people, it is 
not for our hospital to gain money. It is not the Danish way 
to gain something. Savings should go towards the society.” 
Most pharmacists agreed because they considered biosimi-
lar implementation to be part of the job. Some physicians 
mentioned that discounts should be sufficiently substantial 
to offset the effort invested in biosimilar implementation. 
Some argued that the government should take a more active 
role in guiding which product(s) to use.
3.2.2.2 Raising Awareness About Biosimilar Benefits 
and Reporting Usage Data Several physicians and pharma-
cists felt that information about the benefits derived from 
biosimilar use was often lacking but was an important moti-
vational factor for biosimilar use. One regulator mentioned 
• Creating HCP awareness about treatment costs
• Calling on/enforcing the societal responsibility to prescribe in a cost-
effective manner  
• Stimulate the “what is best for society” perspective
• Reinvest savings derived from biosimilar use (predominantly) in the 
healthcare system
• Correct application and transparent organization of tender 
procedures
• Reporting transparently about the gains from biosimilar introduction
• Visualize and report about benefits 
• Communicate about allocation of savings
• Reporting usage data to allow peer-to-peer benchmarking and 
monitoring of purchasing/prescribing
• Among prescribers (prescribing behaviour)
• Among hospitals (purchasing behaviour)
• Can simultaneously instil HCP trust 
• Providing a tangible incentive to compensate for switch effort 
• Incentive towards improving care rather than a personal financial 
benefit
• In terms of extra HCP staff 
• Financial benefit for hospital unit
• Tailoring of incentive proportional to required effort 
• Effort to switch SC products may be larger due to possible 
differences in injection device (training of patients)
• Threshold may be higher for products dispensed outside the 
hospital (less structural support and no tender driving the decision) 
How to motivate stakeholders – a balanced combination of non-tangible and tangible incentives 
Non-tangible incentives Tangible incentives/gainsharing
Fig. 5  How to motivate stakeholders: a balance between non-tangible and tangible incentives (as identified from expert interviews). HCP health-
care professional, SC subcutaneous
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that a powerful incentive for patients to use biosimilars 
would be increased patient access, but some nurses asserted 
that such arguments are not always convincing for patients: 
“You should treat patients at patient level and not tell them, 
‘You create access for many other patients worldwide.’ It’s 
not convincing.” Several patients and nurses explained that 
it is difficult to persuade patients who are satisfied with 
their current treatment to switch. In contrast, one physician 
indicated that a few patients asked to be treated with the 
biosimilar. Earlier treatment access when using a biosimilar 
might be a more convincing incentive, as it could lead to 
a personal benefit for a patient. Overall, several interview-
ees across groups considered that the benefits derived from 
biosimilar use should be communicated more clearly: “As 
sustainability of healthcare is for all of us, we should try to 
stimulate education about the impact of biosimilars as much 
as possible.”
Several patients mentioned that there is no tangible 
incentive for patients to use biosimilars when treatment is 
fully reimbursed and that the willingness to switch may be 
greater in settings where these medicines are only partly 
reimbursed. Furthermore, with regard to motivating patients, 
one Dutch interviewee mentioned that lowering the patient’s 
‘own risk’ insurance payment when agreeing to switch has 
been effective in the Netherlands.
Apart from improving awareness about biosimilar ben-
efits, some physicians believed another stimulus for biosimi-
lar use would be to transparently report biosimilar usage 
data among prescribers and hospitals, as this provides use-
ful insights into colleague prescriber behaviour and, subse-
quently, gives confidence to less experienced stakeholders.
3.2.2.3 Allocation of Savings: Balancing Societal and Stake-
holder Benefits and the Need for Transparency Some HCPs 
and patients felt that the savings should (partially) remain 
at the departmental level or within the therapeutic area that 
helped to realize the savings. Others were indifferent to the 
allocation level as long as savings were reinvested in health-
care. Some interviewees expressed concerns that savings 
would be reinvested towards structural or practical improve-
ments (e.g. hospital infrastructure) and not towards patient 
care per se. Some argued that the government should decide 
on how to allocate savings. Overall, interviewees asked for 
transparency regarding the allocation of money saved.
3.2.2.4 Providing Tangible Incentives When Switching: 
Applying a Gainsharing Model Most physicians and nurses 
and some regulators considered that a tangible incentive 
would be appropriate to compensate stakeholders when 
biosimilar use requires significant HCP effort in terms of 
planning and time, i.e. when switching. Several regulators 
and HCPs considered that physicians lack the motivation to 
invest energy and time in a switch if the impact is solely on 
an overarching, more abstract, financial level. Furthermore, 
it was argued that the incentive should be proportional to the 
effort (e.g. a larger incentive for switching to a subcutaneous 
product, as this may require more time for injection device 
training). Most interviewees considered direct financial ben-
efits on an individual level to be inappropriate but consid-
ered that allocating part of the realized savings to improving 
patient care, such as financial support for the hospital ward 
or hiring new staff (i.e. gainsharing), would be an adequate 
and acceptable stimulus. An additional nurse may help bal-
ance the extra workload and enable more active follow-up of 
the switch. Reinvesting some savings in increased monitor-
ing to reassure patients was mentioned as another gainshar-
ing example. Some physicians mentioned that publication 
opportunities may also be a motivator.
3.2.2.5 Considerations for  Incentive Design in  Hospital vs. 
Ambulatory Care Settings Several physicians highlighted 
that defining incentives for biosimilar implementation in 
ambulatory care, particularly in countries where these are 
not part of the hospital budget, can be challenging. Some 
interviewees deemed that in the hospital context, a tender 
would be a satisfactory lever, lessening the need for accom-
panying incentives. As some pharmacists explained, intro-
ducing a negative incentive by lowering the product reim-
bursement level (e.g. 80% of list price) by payers (such as in 
Belgium) motivated hospitals to organize competitive ten-
ders, ensuring product acquisition costs below the lowered 
reimbursement limit.
4  Discussion
This article is the second part of a study on European multi-
stakeholder learnings about biosimilars. The article out-
lines the considerations of various stakeholders as to how 
to implement biosimilar switching and design incentives to 
stimulate biosimilar use and translates them into practical, 
overarching, and strategic recommendations (as shown in 
Table 1). The results of this study may support HCPs and 
policy makers when planning to improve biosimilar use 
in healthcare systems. We propose that actions be centred 
around the 11 key recommendations outlined in Table 1.
It is important to recognize that most of the expert con-
siderations were related to their experience with anti-tumour 
necrosis factor products. Strategies should ideally be tai-
lored to the treatment setting (hospital vs. ambulatory care, 
chronic vs. shorter-term treatment), product type (more 
simple biologicals vs. more complex mAbs), and patient 
needs. The other strengths and limitations of this study are 
described elsewhere [8].
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In line with findings from the considerable number of 
switch studies conducted over recent years [10, 11], the inter-
viewed experts largely considered switching from a reference 
product to a biosimilar to be a part of clinical care. However, 
stakeholders indicated a need for guidance regarding multiple 
switching, as regulatory guidance predominantly focusses on 
a single switch from a reference product to a biosimilar, and 
a harmonized regulatory position about interchangeability 
across Europe is lacking [10, 11, 18]. A clear Europe-wide 
one-voice regulatory position about interchangeability and 
switching is required to support stakeholders faced with 
switch decisions in Europe. Such a European position will 
require an active request by and collaboration between the 
national regulatory agencies, the EC, and the European Medi-
cines Agency (EMA), and could be taken up by the Heads of 
Medicines Agencies. Also, data regarding multiple switch-
ing between reference products and biosimilars, and between 
biosimilars of the same reference product, have been reported 
[19–25] and are likely to accumulate with increasing experi-
ence, which can further support stakeholders.
There was strong desire for the adoption of a structured 
and collaborative approach to implementing a switch. Further-
more, several switch experiences in clinical practice showed 
the benefits of using a managed switch programme in terms 
of cost savings while maintaining similar patient-reported out-
comes [26, 27]. Opinions on how to involve the patient varied, 
and finding an appropriate balance for sharing information 
was deemed challenging. Overall, tailoring communication 
to the individual patient was considered important.
As also mentioned in previous publications [28–31], 
this study found that stakeholders are concerned about 
mandated switching, as this may result in worse patient-
perceived treatment outcomes because of a possible nocebo 
effect. Involving and aligning HCPs and patients when mak-
ing switch decisions can positively affect acceptance and 
limit nocebo effects. Other strategies to mitigate a possi-
ble nocebo effect include delivering balanced information, 
focussing on treatment equality, explaining the reasons for 
and the benefits of a switch, and conveying the physician’s 
trust in the biosimilar to the patient. As discussed in the first 
article of this series, disseminating switch experiences may 
translate into increased HCP and patient trust [8].
Several strategies to increase stakeholder willingness to 
use biosimilars emerged from the interviews. Although opin-
ions on how to design incentives diverged (and were also 
culturally influenced), incentives to offset the work asso-
ciated with a switch were generally deemed necessary. A 
combination of non-tangible incentives (e.g. calling upon 
Table 1  Multi-stakeholder recommendations—key points for decision makers and healthcare professionals in Europe
Tailoring of strategies to the specific treatment setting, the product type, and stakeholder needs is desirable
HCPs healthcare professionals, RCTs randomized controlled trials
Practical recommendations addressing acute/shorter-term HCP needs regarding switching, supporting HCP biosimilar use
   1.  Communicating about results from RCTs, real-world studies, and clinical experiences regarding (multiple) switching
   2.  Providing a clear, one-voice EU overarching regulatory position regarding the interchangeability of biosimilars
   3.  Developing a multi-stakeholder implementation and communication protocol to guide switching in clinical practice
    a. Guidance development on how to structurally organize a switch with involved stakeholders
    b. Guidance development on communication strategies towards patients, limiting bias and mitigating a possible nocebo effect
    c.  Possibility to allow tailoring of strategies to the context of the treatment setting, product type, and individual patient needs (more detailed 
information provided in Fig. 2)
   4.   Developing and applying a balanced combination of non-tangible and tangible incentives for physicians and other stakeholders to use bio-
similars
    a.  Proportional tailoring of incentives to offset the stakeholder effort invested in biosimilar implementation (i.e. effort may be higher when 
switching subcutaneous products because of possible differences between injection devices)
    b.  Application of a gainsharing agreement, reinvesting a part of the savings towards improving care and lowering the time and effort thresh-
old associated with a switch by, for example, hiring additional staff
Overarching recommendations regarding switching decisions
   5.  Applying a pragmatic switch approach, considering the potential gains vs. longevity of treatment
   6.  Avoiding top-down organized switching, allowing and organizing stakeholder involvement, communication, and alignment
Strategic recommendations towards long-term sustainable competition with biosimilar presence
   7.  Raising awareness about medicine prices and stakeholders’ societal responsibility to use and prescribe medicines in a cost-effective manner
   8.  Communicating publicly and actively about savings/advantages resulting from biosimilar use
   9.  Sharing of biosimilar uptake and prescribing data among hospitals and prescribers to allow peer-to-peer benchmarking
10.  Reporting transparently about the allocation of savings resulting from biosimilar use
11.   Developing policies with a long-term vision, beyond realizing short-term savings and with a focus towards creating a sustainable market 
with presence and competition of multiple suppliers
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societal responsibility and transparent reporting about sav-
ings allocation) and tangible incentives (e.g. extra staff) 
could be applied and tailored to the level of effort required 
in the local and societal context. Gainsharing agreements 
emerged as the preferred way to motivate stakeholders, as 
savings could partially serve to improve local clinical care. 
Visualizing and communicating clearly and transparently 
about biosimilar-related savings and how these are then allo-
cated could improve stakeholder motivation.
As the learnings from this study primarily apply to the 
hospital context, future research could focus on switch and 
incentive approaches tailored to the ambulatory care setting.
5  Conclusion
This study proposes practical and strategic measures to 
improve biosimilar implementation practices and increase 
the willingness of stakeholders to use biosimilars based on 
insights from different stakeholder groups (patients, physi-
cians, pharmacists, nurses, and regulators). Suggested solu-
tions included applying a structured switch and communica-
tion strategy, implementing a combination of non-tangible 
and tangible stakeholder incentives, and actively providing 
information regarding the benefits of biosimilar use. The 
recommendations from this study can support HCPs with 
biosimilar use and decision makers with designing biosimi-
lar policies and stakeholder incentives.
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